Document is current
Any future updates will be listed below
-
Authors
Hüper, Sebastian https://orcid.org/0000-0002-3771-4635
Eisele, Florian https://orcid.org/0009-0009-4305-5718
Duell, Johannes
Schmalzing, Marc https://orcid.org/0000-0002-3289-2299
Nagler, Lea
Strunz, Patrick Pascal https://orcid.org/0000-0002-3168-7074
Froehlich, Matthias https://orcid.org/0000-0001-7745-3903
Portegys, Jan https://orcid.org/0000-0003-3968-2849
Gernert, Michael https://orcid.org/0000-0003-0074-4459
-
Funding
Funding for this research was provided by:
Universitätsklinikum Würzburg
- License Information
-
More Information
Article History
Received: 6 July 2024
Accepted: 25 June 2025
First Online: 9 July 2025
Declarations
:
: The study adhered to the tenets of the Declaration of Helsinki and received approval from the local ethics committee (EC Medical Faculty, University of Wuerzburg No. 258/21). Blood samples were collected after patients had given written informed consent.
: Not applicable.
: SH has received travel grants or speaker`s fess from AbbVie, Janssen-Cilag and UCB.FE has received travel grants from Beigene. JD declares no competing interests. MS has received Compensation for consultancies: Chugai/Roche, Hexal/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer/Ingelheim, onkowissen.de, EUSA-Pharma, Novartis, AstraZeneca, Amgen, medac, Lilly, Galapagos, UCB. Speeker‘s fees: Novartis, AbbVie, AstraZeneca, Chugai/Roche, Janssen-Cilag, Gilead, Boehringer/Ingelheim, Mylan, Galapagos, EUSA-Pharma Travel grants: Chugai/Roche, Boehringer/Ingelheim, Celgene, Medac, UCB, Mylan, Galapagos Grant/research support: Chugai, NovartisLN has received travel grants from travel grants from AbbVie, Medac, UCB.PPS has received speaker’s fees and travel grants from Janssen-Cilag Galapagos, Eli Lilly, Boehringer/Ingelheim and AbbVie (less than $10,000 each) as well as research funding from Chugai (25,000$). MF has received travel grants or speaker`s fees from AbbVie, Janssen, Novartis, Eli Lilly.JP has received travel grants or speaker`s fees from Chugai and AbbVieMG has received travel grants, compensation for advisory boards or speaker’s fees from AbbVie, Amgen, AstraZeneca, Lilly, Hexal, Janssen, Novartis, Pfizer, Takeda, UCB.
